Skip to main content
. 2017 Jun 30;8(46):81052–81061. doi: 10.18632/oncotarget.18898

Table 1. Main characteristics and results of the eligible studies.

NO First author Year Study location No. of patients hystopathological subtypes Cutoff value Antibody Survival Methods of HR estimation Pool HR and 95% CI
OS PFS
1 Darai, E. 1996 France 20 10 serous and 10 mucinous 10% R & D Systems OS Survival curves 1.22 (1.01, 1.42) /
2 Faleiro Rodrigues, C. 2004 Portugal 104 56 serous, 22 mucinous, 16 clear cell, 8 endometrioid and 2 transitional cell 0% Transduction Laboratories, USA OS Given by author 4.83 (1.38, 16.9) /
3 Voutilainen, K. A. 2006 Finland 282 102 serous, 30 mucinous, 74 endometrioid, 30 clear cell, 46 miscellaneous 5% Zymed Laboratories, USA OS Survival curves 1.70 (0.71, 2.69) /
4 Cho, E. Y. 2006 Korea 95 95 serous 10% DiNonA, Seoul, Korea OS Survival curves 1.23 (1.12, 1.80) /
5 Blechschmidt, K. 2008 Germany 48 primary serous 10% Transduction Laboratories, USA OS Given by author 2.82 (1.30, 6.30) /
6 Shim, H. S. 2009 Korea 72 72 serous 25% DAKO, Denmark OS Survival curves 1.82 (1.32, 2.86) /
7 Ho, C. M. 2010 Taipei, China 58 58 Clear Cell 10% DAKO, Denmark OS, PFS Given by author 2.30 (1.10, 4.81) 1.45 (0.75, 2.95)
8 Dian, D. 2011 Germany 100 100 serous 25% DAKO, Denmark OS, PFS Survival curves 1.68 (0.51, 2.85) 1.81 (0.80, 4.10)
9 Huang, K. J. 2012 China 136 No given 5% Santa Cruz, CA OS Given by author 1.15 (0.63, 2.09) /
10 Taskin S. 2012 Turkey 30 30 serous Product > 3 points Zymed Laboratories, USA OS Given by author 9.60 (2.10, 43.60) /
11 Bacic, B. 2013 Croatia 54 54 serous 10% DAKO, Denmark OS Given by author 3.08 (1.54, 6.18) /
12 Huang, H. N. 2014 Taipei, China 72 72 clear cell 10% DAKO, Denmark OS, PFS Given by author 0.70 (0.31, 1.58) 0.71 (0.32, 1.56)
13 Wang, Y. 2014 China 54 No given 10% Santa Cruz, CA OS Given by author 2.92 (1.52, 3.24) /
14 Mise, B. P. 2015 Croatia 98 98 Serous 10% DAKO, Denmark OS, PFS Given by author 2.70 (1.30, 5.90) 1.35 (0.70, 2.70)
15 Liew, P. L. 2015 Taipei, China 108 47 serous, 23 mucinous, 13 endometrioid and 25 clear cell Not given DAKO, Denmark OS, PFS Given by author 1.15 (0.58, 2.31) 0.92 (0.46, 1.85)
16 Yu, L. 2015 China 150 114 serous, 21 mucinous, 9 endometrioid and 6 clear cell Product = 2 points Maixin, Fuzhou, China OS Survival curves 1.99 (1.06, 3.74) /
17 Sundov, D 2017 Croatia 81 81 serous 10% DAKO, Denmark OS Survival curves 3.30 (1.90–5.80) /